Effect of pioglitazone on platelet aggregation in a healthy cohort

Cardiology

Volumn 116, Issue 4, 2010, Pages 253-256

  Chokesuwattanaskul, Warangkana ^a   Yaqub, Yasir ^b   Suarez, Jose A ^a   Simoni, Jan ^b   Simoni, Grace ^b   Nugent, Kenneth M ^b   Jimenez, Rosalinda ^a   Perez Verdia, Alejandro ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Peroxisome proliferator activated receptor; Pioglitazone

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; CHOLESTEROL; COLLAGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; DEMOGRAPHY; DRUG EFFECT; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ADULT; ARACHIDONIC ACID; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; COLLAGEN; DIABETES MELLITUS, TYPE 2; EPINEPHRINE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 77956065149     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318024     Document Type: Article

References (21)

1. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, PROactive investigators, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289.
2. Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, Jackson SK, Evans LM: Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus - an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis 2008; 197: 718-724.
3. Winkler K, Konrad T, Fullert S, Friedrich I, Destani R, Baumstark MW, et al: Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 2003; 26: 2588-2594.
4. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, et al: Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-2499.
5. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
6. Sidhu JS, Cowan D, Kaski JC: The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-1763.
7. Marx N, Libby P, Plutzky J: Peroxisome proliferator- activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk 2001; 8: 203-210.
8. Walker AB, Chattington PD, et al: The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48: 1448-1453.
9. Pasceri V, Willerson JT, Wu HD, Yeh ET: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferatoractivated receptor-gamma activators. Circulation 2000; 101: 235-238.
10. Marx N, Collins T, Sukhova GK, et al: PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99: 3125-3131.
11. Rosenson RS: Effects of peroxisome proliferator- activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus. Am J Cardiol 2007; 99: 96B-104B.
12. Festa A, D'Agostino R Jr, Howard G, et al: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
13. Li D, Chen K, Sinha N, Zhang X, Wang Y, Sinha AK, Romeo F, Mehta JL: The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 2005; 65: 907-912.
14. Borchert M, Schöndorf T, Lübben G, Forst T, Pfützner A: Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function. Diabetes Technol Ther 2007; 9: 410-420.
15. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605-1611.
16. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
17. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
18. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930-934.
19. Sidhu JS, Cowan D, Tooze JA, Kaski JC: Peroxisome proliferator-activated receptorgamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 2004; 147:e25.
20. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP: Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004; 104: 1361-1368.
21. Simoni J, Simoni G, Wesson DE, Griswold JA, Feola M: A novel hemoglobin-adenosineglutathione based blood substitute: evaluation of its effects on human blood ex vivo. ASAIO J 2000; 46: 679-692.